Kelun-Biotech’s ASCO 2026 data strengthens China’s next wave of targeted cancer drugs
Kelun-Biotech’s RET lung cancer data looks strong, but CNS durability and global competition will decide its real impact.
Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?
A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.
Why Ono’s Phase 2 MSA data may matter beyond one World Parkinson Congress poster
Ono’s ONO-2808 data hints at disease modification in MSA. See why Phase 3 may decide whether the signal becomes a breakthrough.
Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Charles River and MEDIPOST deepen cell therapy testing push across APAC and North America
Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.
Why GSK’s SBP Group alliance could reshape chronic hepatitis B access in Chin
China has hepatitis B scale. GSK has bepirovirsen. SBP Group may decide whether science can become real-world access.
Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market
ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.
FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy
Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.
Why Wenda Pharma’s Phase II data puts BET inhibition back in focus for NUT carcinoma
NUT carcinoma has few options and poor survival. Wenda Pharma’s NHWD-870 may test how fast China can move rare oncology forward.
Could LANGLARA finally crack the high-cost insulin access problem in the United States?
Insulin access needs more than approvals. LANGLARA’s real test is whether payers and pharmacies turn interchangeability into savings.